NasdaqCM:CELCBiotechs
A Look At Celcuity (CELC) Valuation After Positive VIKTORIA-1 Data And FDA Priority Review
Celcuity (CELC) has moved into focus after reporting Phase 3 VIKTORIA-1 data for gedatolisib and securing FDA Priority Review, alongside a newly priced US$500 million convertible senior notes offering due 2032.
See our latest analysis for Celcuity.
Despite the positive Phase 3 VIKTORIA-1 data and FDA Priority Review, Celcuity’s share price has pulled back sharply in recent weeks, with a 30 day share price return of down 33.3%, even as the 1 year total shareholder return is very large and...